Results 211 to 220 of about 182,106 (353)

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are available in two fixed‐ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide.
Kevin Cowart, Nicholas W. Carris
wiley   +1 more source

Efficacy and outcomes of dapagliflozin in diabetic nephropathy: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Dahal K, Rawal L, Shah S, Bhattarai M, Bhattarai HB, Acharya A, Bhandari S, Paudel A, Sah S, Mehta R, Gupta A.   +10 more
europepmc   +1 more source

Evaluation and surgical management of emergency operation, including that for diabetic nephropathy, in hemodialysis patients.

, 1990
Kouji Soeda, Michio Odaka, Yoichiro Tabata, Kaichi Isono, Toshitsune Shimada, Hiroshi Nishijima, Soichiro Toyoizumi   +6 more
openalex   +2 more sources

The impact of a family history of Type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with Type I (insulin-dependent) diabetes mellitus [PDF]

, 1999
Johan Fagerudd, Kim Pettersson-Fernholm, Carola Grönhagen‐Riska, Per‐Henrik Groop   +3 more
openalex   +1 more source

Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT‐2 and STEP 2.
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Marine Bertrand, Tristan Curteis, Laura J. Clark, Ludi Fan, Helene Sapin, Jean‐Francois Bergmann   +9 more
wiley   +1 more source

Regulation of pyroptosis in diabetic nephropathy by long non-coding and circular RNAs. [PDF]

Clin Exp Med
Hushmandi K, Klionsky DJ, Farahani N, Reiter RJ, Imani Fooladi AAI, Alimohammadi M, Aref AR.   +6 more
europepmc   +1 more source

Diabetic nephropathy: from micro- to macroalbuminuria [PDF]

, 1998
G. Defarrari
openalex   +1 more source

PIONEER REAL Spain: A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks ...
Elías Delgado Álvarez, Cristóbal Morales Portillo, Cristina Abreu Padín, Alberto Aliaga Verdugo, Ana Piera Carbonell, Aída Cadenas González, Jaime Amor Valero, Verónica González López, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Diego Bellido Guerrero   +10 more
wiley   +1 more source

Role of exosomes in pathogenesis, diagnosis, and treatment of diabetic nephropathy. [PDF]

BMC Nephrol
Barr SI, Abd El-Azeem EM, Bessa SS, Mohamed TM.   +3 more
europepmc   +1 more source

Dietary treatment of diabetic nephropathy with chronic renal failure [PDF]

, 1998
Giovanni Barsotti
openalex   +1 more source